Opinion|Videos|December 18, 2024

Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

Key Takeaways

Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME